Annual Report for the year ended 30 June 2024

Argent Biopharma Limited

30 September 2024

 

30 September 2024

Argent BioPharma Ltd.

(Argent BioPharma or the Company)

Annual Report for the year ended 30 June 2024

and ASX Corporate Governance Statement

Argent BioPharma, an innovative multidisciplinary drug discovery company within the biopharmaceutical sector is pleased to provide the following documents in respect of the financial year ended 30 June 2024:

·    Annual Financial Report (Audited)

A copy of the Company's Annual Financial Report for the year ended 30 June 2024 can be found at the following URL:

https://www.investi.com.au/api/announcements/rgt/f19a9293-4b8.pdf

·    ASX Appendix 4G "Key disclosures - Corporate Governance Council Principles and Recommendations" and Argent BioPharma's Corporate Governance Statement

A copy of the Company's ASX Appendix 4G - Corporate Governance Disclosures & Corporate Governance Statement can be found at the following URL:

https://www.investi.com.au/api/announcements/rgt/81d037ff-a07.pdf

-Ends-

Authorised for release by the board of directors, for further information please contact:

Argent BioPharma Roby Zomer CEO & Managing Director [phone] [e-mail]

Argent BioPharma Rowan Harland Company Secretary [phone] [e-mail]

About Argent BioPharma

Argent BioPharma Limited (the Company) (ASX: RGT; LSE: RGT; OTCQB: RGTLF) an innovative multidisciplinary drug development Company within the biopharmaceutical sector.  The Company focuses on multidisciplinary methods with Nanotechnology, developing multi-target therapies for comprehensive disease management, especially concerning the Central nervous system (CNS) and Immunology treatments.

Follow us through our social media channels:

LinkedIn: Argent BioPharma

Twitter: @ArgentBioPharma

Facebook: Argent BioPharma

 

END